Compare ADMA Biologics Inc (ADMA) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Suncor Energy Inc. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Suncor Energy Inc. trades at $63.2 (market cap $73.34B). The key difference: Suncor Energy Inc. is far larger — about 33.6× ADMA Biologics Inc's market cap, and Suncor Energy Inc. pays a 2.72% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SU | |
|---|---|---|
Market Cap | $2.18B | $73.34B |
Sector | Health | Energy |
52-Week High | $20.38 | $69.73 |
52-Week Low | $7.60 | $38.17 |
Enterprise Value | $2.25B | $80.01B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Suncor Energy (SU) trades at $60.1, down 2.04% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.27, beating estimates, and maintains a strong balance sheet with $3.48B in cash. Valuation ratios appear attractive with a P/E of 11.24 and EV/EBITDA of 5.42. Recent news highlights leadership changes, with Peter Zebedee set to become CEO in 2027.
Outlook is mixed: strong cash flow and analyst buy ratings (74% consensus) support upside, but near-term technical weakness and operational challenges from weather impacts pose risks. The stock offers value with solid profitability (ROE 19.25%) but faces volatility from oil price fluctuations and execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
